1. Home
  2. REVB vs XBIO Comparison

REVB vs XBIO Comparison

Compare REVB & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • XBIO
  • Stock Information
  • Founded
  • REVB 2020
  • XBIO N/A
  • Country
  • REVB United States
  • XBIO United States
  • Employees
  • REVB N/A
  • XBIO N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • XBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • REVB Health Care
  • XBIO Health Care
  • Exchange
  • REVB Nasdaq
  • XBIO Nasdaq
  • Market Cap
  • REVB 3.7M
  • XBIO 4.2M
  • IPO Year
  • REVB N/A
  • XBIO N/A
  • Fundamental
  • Price
  • REVB $0.79
  • XBIO $3.53
  • Analyst Decision
  • REVB
  • XBIO Hold
  • Analyst Count
  • REVB 0
  • XBIO 1
  • Target Price
  • REVB N/A
  • XBIO N/A
  • AVG Volume (30 Days)
  • REVB 3.0M
  • XBIO 169.6K
  • Earning Date
  • REVB 08-08-2025
  • XBIO 08-12-2025
  • Dividend Yield
  • REVB N/A
  • XBIO N/A
  • EPS Growth
  • REVB N/A
  • XBIO N/A
  • EPS
  • REVB N/A
  • XBIO N/A
  • Revenue
  • REVB N/A
  • XBIO $2,582,728.00
  • Revenue This Year
  • REVB N/A
  • XBIO $14.23
  • Revenue Next Year
  • REVB N/A
  • XBIO $7.14
  • P/E Ratio
  • REVB N/A
  • XBIO N/A
  • Revenue Growth
  • REVB N/A
  • XBIO 5.63
  • 52 Week Low
  • REVB $0.74
  • XBIO $2.20
  • 52 Week High
  • REVB $56.00
  • XBIO $5.27
  • Technical
  • Relative Strength Index (RSI)
  • REVB 26.64
  • XBIO 58.63
  • Support Level
  • REVB $0.74
  • XBIO $2.65
  • Resistance Level
  • REVB $0.88
  • XBIO $5.27
  • Average True Range (ATR)
  • REVB 0.06
  • XBIO 0.45
  • MACD
  • REVB 0.08
  • XBIO 0.09
  • Stochastic Oscillator
  • REVB 32.49
  • XBIO 33.61

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Share on Social Networks: